The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB1 receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB1 antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation – MDA) in the rat. WIN55,212-2 (21 mg kg−1) exerted an anticonvulsant effect, significantly reduced by the pre-treatment with AM251 (1 mg kg−1, 30 min interval). Surprisingly, AM251, administered alone at the same dose, failed to induce any modification in MDA responses. Our data suggest the involvement of the CB system in the inhibitory control of hyperexcitability phenomena in a model of acute partial epilepsy. Although the MDA model per se does not induce a basal activation of CB1 receptors, as suggested by the lack of efficacy of AM251 when administered alone, the partial suppression of WIN55,212-2-induced effects in rats pre-treated with AM251 allows to hypothesise that the WIN55,212-2-induced antiepileptic effect is strictly linked to an increased CB1 receptor activation or to the involvement of further receptor subtypes.
|Numero di pagine||5|
|Stato di pubblicazione||Published - 2009|
All Science Journal Classification (ASJC) codes